Velcade shows improved OS in Multiple Myeloma- Takeda
Takeda has announced results from a retrospective, subgroup analysis of the Phase III VISTA study that showed a higher cumulative dose of Velcade (bortezomib) suggests improved overall survival in previously untreated patients with Multiple Myeloma (MM). Patients who received a cumulative dose of Velcade of 39 mg/m2 or greater lived 20 months longer on average than those who received lower cumulative doses (median OS 66.3 months and 46.2 months, respectively). The subgroups were determined post-randomization and the analysis was retrospective.
The retrospective analysis was conducted using data from the VISTA study, which evaluated the safety and efficacy of a Velcade-melphalan-prednisone (VMP) regimen of up to 54 weeks compared with melphalan-prednisone (MP) alone in patients with previously untreated MM. These data were presented at the 55th American Society of Hematology (ASH) annual meeting. Velcade is approved by the FDA for the treatment of MM and relapsed Mantle Cell Lymphoma.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.